UPDATE: Mizuho Securities Upgrades Cubist Pharmaceuticals on Pending Acquisitions of Optimer and Trius
In a report published Wednesday, Mizuho Securities analyst Mario Corso upgraded the rating on Cubist Pharmaceuticals (NASDAQ: CBST) from Neutral to Buy, and raised the price target from $50.00 to $77.00.
In the report, Mizuho Securities noted, “We are upgrading our rating on CBST shares to Buy from Neutral with a price target of $77 vs. $50 previously. We have added the pending acquisitions of Optimer and Trius to our financial models, deriving DCF valuations of $77, $96 and $51 in three different revenue/EPS scenarios. Catalysts for achieving our price target are the transactions closing/integration by year end 2013, CBST financial guidance in early 2014, CXA-201 Phase III data by year end, and FDA approval of tedizolid toward mid-2014.”
Cubist Pharmaceuticals closed on Tuesday at $61.59.
Latest Ratings for CBST
|Nov 2014||Credit Suisse||Downgrades||Outperform||Neutral|
|Nov 2014||SunTrust Robinson Humphrey||Initiates Coverage on||Buy|
|Nov 2014||Wedbush||Initiates Coverage on||Neutral|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.